Institutional investors hold a majority ownership of ALXN through the 97.36% of the outstanding shares that they control. This interest is also higher than at almost any other company in the Biotechnology industry. Last, during the quarter ended March 2017, these large investors purchased a net $6.7 million shares.
Mutual fund holders
Largest Quarterly Institutional Transactions
Latest Institutional Activity
JENNISON ASSOCIATES LLC Bought 1.3 Million shares of Alexion Pharmaceuticals I...